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Risk scoreDeaths due to coronary heart disease (CHD) remain high worldwide, despite recent achievements. An effective
screening strategy may improve outcomes further if implemented in a high or ‘at risk’ cohort. Asymptomatic
CHD in the young maybe underappreciated and applying an effective screening strategy to a young cohort
may lead to improved outcomes due to signiﬁcant socioeconomic impact from the consequences of CHD in
this sub-group. A positive family history of CHD, which is known to be associatedwith an increased risk of future
myocardial events, could aid in identifying the ‘at risk’ young cohort.
Traditional cardiovascular risk scoring systems are in wide use but lack the sensitivity or speciﬁcity required to
estimate risk in an individual. Rather their use is limited to predicting population attributable risk. Functional
studies such as exercise stress tests are readily available and cost effective but do not have the required sensitivity
required to suggest their use as part of a screening protocol. Coronary CT angiography has been demonstrated to
have high sensitivity for the detection of CHD and thereforemay be suitable for screening purposes but there are
concerns regarding radiation exposure.
Here we review the evidence for the use of potential screening strategies and the suitability of using such
strategies to estimate risk of CHD in a young ‘at risk’ population.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Coronary heart disease (CHD) remains the primary cause of death
worldwide [1]. There is general agreement regarding the need for inves-
tigation of symptomatic patients suspected of CHD and subsequent
instigation of therapies [2,3]. Screening asymptomatic individuals,
however, is controversial but potentially allows early detection and
more accurate risk estimation [4]. Estimating risk in any one individual
is important not only for implementation of effective management
strategies but also for reassurance and psychosocial security. In some
cases, the ﬁrst presentation of CHD maybe myocardial infarction (MI)
orworse, sudden cardiac death (SCD) [5]. Screeningmay allow detection
of occult CHD prior to such catastrophic events. That said, while these
catastrophic events are often associated with CHD, silent or asymptom-
atic ischemia may account for more than 75% of ischemic episodes [6].
Identifying asymptomatic disease is only useful if disease progres-
sion can be altered [7]. Dietary and pharmacological interventions
have been shown to reducemorbid cardiovascular events in asymptom-
atic individuals [8–11] although the published data did not speciﬁcally, Western Hospital, Footscray,
3 8345 7357.
land Ltd. This is an open access articlefocus on a young cohort. Both the PREDIMED and the JUPITER studies
enrolled participants without known CHD and were able to demon-
strate a reduction of major cardiovascular events with administration
of a Mediterranean diet and a statin respectively [8,10]. Screening of
the general population is not cost effective [7], hence a mechanism is
required to identify ‘at risk’ individuals.
Risk of CHD can be estimated in any individual via risk scores, and
this can be further reﬁnedwith functional andnon-functional investiga-
tions. Here we review existing risk estimation tools, potential screening
modalities and the appropriateness of implementing them in estimating
risk of CHD in the young.
1.1. CHD in the ‘young’
20% of men as young as 34 has been shown to have advanced coro-
nary artery lesions [12]. The Framingham Heart Study demonstrated a
rate of MI in men and women between the ages of 30–44 of 51.1/1000
and 7.4/1000 respectively [13]. A higher rate of MI of between 4% and
10% among those aged ≤45 years was reported in other studies with
the vast majority of them beingmale [14–16]. 20% of MI has been dem-
onstrated to occur in the young in an urbanized Australian population
[17]. It of course stands to reason that the prevalence of asymptomatic
CHD in the young is higher. There is some evidence to suggest that the
prevalence may be even higher in a socioeconomically deprived areaunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MI of the young.
The manifestation of developing heart disease at a young age can be
psychologically and economically challenging not only for the individu-
al but also for family members and especially siblings whomay fear for
their own health. Family history of premature CHD is known to be a risk
factor for CHD [19,20] but is lacking in the widely accepted risk scores.
The prevalence of family history of CHD in young MI patients has been
reported as high as 64% [16,21,22]. In the Framingham Offspring
Study, presence of sibling CHD increases the risk of a cardiovascular
event in young adults by almost two fold [23]. It can therefore be hy-
pothesized that siblings of patients who experience MI at a young age
maybe at increased risk of asymptomatic CHD and future premature
MI. Yusuf et al [20] demonstrated the importance of family history as
a risk factor for MI particularly in young patients. With the aid of an
effective screening tool premature CHD could potentially be identiﬁed
in these individuals.
Screening asymptomatic patients for subclinical CHD could be
equally important in young andold populations at risk. This paper, how-
ever, speciﬁcally focuses on a younger population because of signiﬁcant
socioeconomic impact from the consequences of CHD in this sub-group.
The application of an effective screening strategy to the young is likely
to lead to large clinical and social successes due to their increased poten-
tial life expectancy. As we have already discussed, screening an entire
population to identify this group is neither cost effective nor feasible.
Hence identiﬁcation of the ‘at risk’ group is paramount in implementa-
tion of any screening tool.
2. Estimating risk
The contemporary “gold standard” for detection of CHD is the
catheter-based coronary angiogram. Catheter based selective coronary
angiography, however, is an invasive procedure that is associated with
a small but signiﬁcant risk of life threatening complications such as
stroke, bleeding and MI [24]. Hence, catheter-based coronary angiogra-
phy is not suitable as a screening tool or a method of estimating risk of
CHD.
The concept of screening requires not only a cost-effective strategy
but also clearly established treatment or disease modifying tools for
the pathology being screened for [7]. It must also be safe and accurate,
with high sensitivity in order to detect disease [7]. Screening must be
targeted at disorders with high prevalence [7], and CHD appears to be
perfectly positioned in this respect. Existing screening programs such
as strategies aimed at detecting colorectal carcinoma via fecal occult
blood testing (FOB) [25] and breast carcinoma via mammography [26]
demonstrate many of these qualities. Controversies do exist regarding
the use of FOB and mammography, however, overall they are regarded
beneﬁcial and potentially helpful in mitigating the risk of late detection
and its consequences.
2.1. Risk scores
Risk scores are based on the premise that an individual's total bur-
den of risk factors for CHD is more predictive than the level of any one
particular risk factor. They predict a statistical population attributable
risk but lack sensitivity or speciﬁcity in identifying an individual's risk
[27].
Perhaps themost well known risk scoring system in the ﬁeld of CHD
originated from the Framingham Heart Study [28]. This study utilized
observational data to formulate a risk estimation system based upon
categorical variables where an individual's risk of having a CHD event
is predicted at 10 years. The variables incorporated are age, presence
of diabetes, smoking, blood pressure and total and LDL cholesterol.
The receiver-operating characteristic (ROC) curve c-statistic of the
model (using total cholesterol as a variable) is 0.73 and 0.76 in men
and women respectively. A c-statistic of greater than 0.7 typicallysuggests a reasonable model [29]. There are a number of factors associ-
ated with this tool that may not necessarily make it universally applica-
ble however. It was a single center study, based in the United States of
America, and focused on a middle-aged white cohort with data from
the early 70s.
The contemporary Interheart study sought to overcome some of
these limitations [20,30]. It was a large case-control study of acute MI
in 52 countries that attempted to represent every inhabited continent.
The risk factors required for estimation of risk are age, apolipoprotein
B:A1 ratio, smoking, passive smoking, presence of diabetes and hyper-
tension. Validation of the score was demonstrated across an interna-
tional population with consistent results across ethnic groups and
geographic regions [30]. An area under the ROC curve c-statistic of
0.71 was established.
A risk scoring system developed speciﬁcally for Europe was pub-
lished in 2003. The Systemic Coronary Risk Evaluation (SCORE) project
was established due to concerns of applying the Framingham Risk
Score to a European cohort [31]. Data were derived from 12 European
countries and comprised over 200,000 people. Variables of the score
are age, sex, blood pressure, smoking and either total cholesterol or
cholesterol/HDL ratio. Contrary to the other two risk factors described
above, SCORE aims to predict fatal cardiovascular risk rather than CHD
risk. Areas under the ROC curve for this risk scoring system are between
0.71 and 0.84 [31] over the differing geographical locations studied.
2.2. Exercise stress test
The simple exercise stress test (EST) or exercise electrocardiograph
(ECG) is a mainstay of investigating patients suspected of CHD, but it
has also been utilized as a screening tool due to the correlation demon-
strated between asymptomatic or silent ischemia and CHD mortality
[32,33]. Rautaharju et al [32] and Ekelund et al [33] showed the
potential of a positive EST to predict the risk of cardiac death. It appears,
however, that the exercise capacity of an individual during exercise
rather than ST changes, which is usually the factor used to discriminate
between a normal and abnormal test, maybe the better discriminator of
outcome [34].
Presence of risk factors strongly affects the pretest probability of an
EST [35,36]. The relative risk of CHD mortality if an individual has 3 or
more risk factors and an abnormal EST is 80 [35] with a 5.9 fold in-
creased in CHD mortality for a smoker with silent ischemia [36]. EST
can predict CHD deathwith high speciﬁcity of 89%, but this is countered
against relatively poor sensitivity of 61%, as demonstrated by Gibbons
et al [35].
The published literature is biased when describing the diagnostic
accuracy of EST as most of the studies include symptomatic rather
than asymptomatic individuals. The EST studies discussed above focus
on mortality and hence cannot be used to evaluate the sensitivity and
speciﬁcity of EST in detecting asymptomatic CHD. For this onewould re-
quire all patients with a negative EST to undergo coronary angiography.
A review suggests speciﬁcity and sensitivity of approximately 80% and
50% respectively of EST in an asymptomatic cohort [37]. Data from a
meta-analysis, not exclusively looking at asymptomatic individuals, re-
port wide variability with sensitivity and speciﬁcity of 68 ± 16% (SD)
and 77 ± 17% (SD) respectively [38].
EST is usually only viable if the underlying ECG is normal and is de-
pendent on an individual being able to exercise. Hence it is not suitable
for all individuals.
2.3. Exercise myocardial perfusion imaging
Radionuclide myocardial perfusion imaging (MPI) may be utilized
for the detection of CHD and thereby to estimate individual risk. The
uptake of tracer by themyocardium can be detected and acts as a surro-
gate for the presence and magnitude of CHD. It can therefore also be
used to identify ischemia of speciﬁc myocardial territories. Similar to
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adequate level of exercise and therefore heart rate being achieved
[39]. Also, as with EST, certain ECG abnormalities can impair the predic-
tive value ofMPI. In particular left bundle branch block can provide false
positives indicating myocardial ischemia of the septum [40].
Meta-analysis of weighted pooled results has demonstrated 87%
(95% CI, 86%–88%) sensitivity of MPI for diagnosis of CHD but relatively
poor speciﬁcity of 64% (95% CI, 60%–68%) [41]. This could potentially
lead to further unnecessary invasive investigations due to false posi-
tives. If one restricts the positive deﬁnition of this modality to multiple
myocardial distributions rather than single territories then the speciﬁc-
ity increases to 87% (95% CI, 85%–89%) but at the cost of a much lower
sensitivity of 44% (95% CI, 38%–49%) [41]. Conversely however the
accuracy of MPI in detecting left main and triple vessel coronary artery
disease is low [42]. Kwok et al [43] demonstrated that 26% of patients
had triple vessel or left main coronary artery disease where the MPI
was abnormal in only a single coronary territory.
The balance of evidence for the usefulness of MPI is weighted in the
direction of symptomatic rather than asymptomatic individuals due to
lack of data. Blumenthal et al [44] however conducted a study concen-
trating on asymptomatic siblings of persons with documented CHD.
They demonstrated a high false positive rate of MPI with only 25% of
participants who had a positive MPI having angiographically signiﬁcant
disease as deﬁned by coronary stenosis greater than 70%.
As with anymodality utilizing radiation, the exposure to the patient
always needs to be taken into consideration. This is of particular impor-
tancewith the cumulative exposure of repeated studies. Radiation doses
between 8mSv and 30mSv have been reported for MPI [45] depending
on the isotope and protocol choices.
2.4. Exercise stress echocardiography
CHDmay be detected by demonstration ofwallmotion abnormalities
with the aid of two-dimensional stress transthoracic echocardiography.
Myocardial stress is typically inducedwith exercise or pharmacotherapy
using agents such as adenosine, dipyridamole or dobutamine. Use of do-
butamine has been associated with achieving the optimum combination
of sensitivity and speciﬁcity [46].
Meta-analysis data, not exclusively concentrating on asymptomatic
patients, suggest sensitivity and speciﬁcity of 85% (95% CI, 83%–87%)
and 77% (95% CI, 74%–80%) respectively [41]. Marwick et al [47] have
validated a high positive predictive value of 89% for stress echocardiog-
raphy, but this was offsetwith a relatively low negative predictive value
of 61%. In addition Marwick et al [47] reported reduced sensitivity of
stress echocardiography in patients unable to tolerate dobutamine
and therefore unable to reach target heart rate. The negative predictive
value of stress echocardiography for prediction of MI and cardiac death
however appears to be better at 98% [48].
Once again data on the asymptomatic cohort is lacking. In a small
study conducted by Bacci et al [49], on 35 asymptomatic patients with
type 2 diabetesmellitus, the sensitivity and speciﬁcity of stress echocar-
diography was demonstrated to be 21% and 94% respectively. This may
not be applicable to a non-diabetic cohort however, and the diagnostic
accuracy of stress echocardiography in an all comer asymptomatic
cohort is unknown.
Unlike MPI which can be semi-automated, the interpretation of
stress echocardiography is subjective and dependent on the experience
of the clinician [50]. Certain patient characteristics such as presence of
left ventricular hypertrophy, left bundle branch block and high body
mass index may be associated with erroneous results and therefore
preclude its use in certain patient groups [47].
The use of stress echocardiography as a screening test for CAD may
be appropriate given the relative high sensitivity and speciﬁcity that
have been demonstrated. Also it has been shown to be at least as cost
effective as MPI [51] but without the added potential risk of radiation
that would be associated with MPI.2.5. Coronary artery calcium scoring via computer tomography (CT)
Currently 64-detector multidetector row computer tomography
(MDCT) can be used to quantify coronary artery calciﬁcation (CAC)
and allow representation via the Agaston score [52]. The sensitivity of
CAC for detection of coronary stenosis ≥50% has been demonstrated
to be as high as 91% but with a high variance of between 68 and 100%
[53]. Speciﬁcity in the literature is reported to be as low as 49% but
again with a wide range between 21 and 100% [53]. Similarly high neg-
ative predictive values of up to 100% and 97% with low positive predic-
tive values of 66% and 62% in females and males respectively have been
reported although this was for a low threshold score of between 0 and
20 [54]. As with many modalities the sensitivity drops with increasing
threshold cut off CAC scores, and Budoff et al [55] have shown a sensitiv-
ity of 98% for CAC score N 0 and as low as 60% for CAC score of N400.
There is a correlation between age and degree of coronary calcium
with higher CAC scores found in higher age groups [54]. Haberl et al
[54] demonstrated an area under the ROC curve of N0.75 for all age
groups for coronary stenosis ≥50%.
CAC has been shown to predict CHD events in an asymptomatic co-
hort with a relative risk of 10.5 and 2.6 in men andwomen respectively
[56]. The accuracy of prediction for future CHD events appears to be re-
lated to the degree of coronary calciﬁcationwith a sensitivity of 89% and
53% for CAC threshold cut off score of 100 and 680 respectively [57]. CAC
appears a better predictor of mortality over the traditional risk scores
described above and is also able to accurately reclassify risk from inter-
mediate to low and high risk [58,59].
2.6. Coronary CT angiography (CCTA)
CT can be utilized not only to determine the amount of calcium bur-
den but also allows indirect visualization of the coronary arteries and
therefore ﬁlling defects. Although MDCT scanners have high temporal
resolution image acquisition, and therefore quality, it is still dependent
on achieving a low enough heart rate, typically around 60–70 beats/
min. It involves injection of iodinated contrast and therefore maybe
contraindicated in certain individuals such as thosewith history of con-
trast allergy.
When considering the sensitivity and speciﬁcity of CCTA it is
common for the literature to include evaluation at the patient level
(i.e. patient has signiﬁcant CHD or not) and at the segment level (accura-
cy of identifying site of CHD). For asymptomatic patients, the literature
concentrates on patient level evaluation. With respect to patient level
evaluation, Budoff et al demonstrated high sensitivity for CCTA of 95%
(95% CI, 85%–99%) with modest speciﬁcity of 83% (95% CI, 76%–88%)
for detection of≥50% coronary artery stenosis [60]. Positive andnegative
predictive values were 64% and 99% respectively. Miller et al however
established a lower sensitivity of 85% (95% CI, 79%–90%) with a higher
speciﬁcity of 90% (95% CI, 83%–94%) [61]. Meanwhile Meijboom et al
revealed the highest sensitivity of 99% (95% CI, 98%–100%) but with a
correspondingly low speciﬁcity of 64% (95% CI, 55%–73%) [62]. A systemic
review published in 2008 conﬁrms the high sensitivity of CCTA at 98%
with comparatively low speciﬁcity of 88% [63].
CCTA has been utilized to detect asymptomatic CHD in young adults.
Ha et al demonstrated CHD in a population of adults under the age of
40 years with a prevalence of N10% [64]. They also illustrated increasing
prevalence in higher risk groups that were determined via a risk scoring
tool.
The utility of CCTA extends beyond the detection of ≥50% coronary
artery stenosis as even the detection of nonobstructive (≤50% coronary
artery stenosis) plaque allows risk to be predicted due to the relation-
ship between nonobstructive coronary plaque and increased mortality
[65,66]. Other imaging modalities such as intravascular ultrasound
and optical coherence tomography have been demonstrated to be use-
ful in predicting the vulnerability of these mild plaques and thereby
allow prediction of future acute coronary syndromes [67,68]. These
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fore not suitable for screening.
Limitations of this modality include patient factors such as tachycar-
dia, arrhythmias and inability to breath hold. As with many modalities
increasing age can reduce the effectiveness and in the case of CCTA
severe coronary calciﬁcation, which often coexists in the elderly, can in-
terfere with image reconstruction. Radiation dose was an initial concern
in the previous generations of MDCT scanners with effective doses up to
10.5 mSv [69]. With contemporary technology, however, the radiation
dose can be reduced to well below 2 mSv, which approximates to the
Australian annual background radiation dose [70]. That level of radiation
exposure is estimated to result in an excess lifetime cancer risk of
approximately 42/100 000 men and 62/100 000 women [69].
3. Current practice guidelines
3.1. American College of Cardiology Foundation/American Heart Associa-
tion (ACC/AHA)
The ACC/AHA Task Force Practice Guidelines discuss screening for
asymptomatic cardiovascular disease using the modalities described
above [71]. The use of EST is suggested for intermediate-risk (6–10%
10 year risk) adults but only with a class IIb recommendation, and im-
portance is given to non-ECG markers as a surrogate for a positive test
such as exercise capacity. Stress echocardiography is not recommended,
and the use of MPI is suggested only for those with diabetes or for those
with a strong family history of CHD but again with a relatively weak
class IIb recommendation. They suggest CAC to guide risk assessment
in individuals at intermediate (10–20% 10-year risk) risk (class IIa rec-
ommendation) and low to intermediate (6–10% 10-year risk) risk
(class IIb recommendation) but not for low (b6% 10-year risk) risk.
CCTA was not recommended as a screening tool due, mainly, to a lack
of evidence.
3.2. European Society of Cardiology (ESC)
The recommendation for the use of EST in cardiovascular risk assess-
ment by the ESC is comparable to that of the ACC/AHA with a class IIb
recommendation and similar emphasis focused on non-ECG markers
[72]. The ESC suggests use of CAC for cardiovascular risk assessment in
asymptomatic adults at moderate (SCORE risk assessment 1— b 5%
10-year risk) risk with a grade IIa recommendation and alludes to the
use of CCTA in the same group [72].
4. Discussion
Here we have presented various potential modalities and tools that
can be used to estimate the risk of CHD and related mortality of an
individual. Most of the data discussed however were not derived from
studies aimed at screening asymptomatic patients and concentrates
on patients aged over 50 years of age. As a result of this lack of data it
is difﬁcult to objectively review the modalities discussed above when
considering their use for potential risk estimation in an asymptomatic
cohort, and therefore if the aim is to deﬁne the risk of CHD in a young
‘at risk’ group the application of these data to formulate a screening
tool may not be appropriate.
If we hypothesize that a substantial number of patientswith a strong
family history of MI have signiﬁcant CHD despite being asymptomatic
then early detection of disease by imaging and non-invasive functional
testsmay have a signiﬁcant role in primary prevention and thereby lead
to improved long term outcome. Currently available risk predictive
algorithms may not be accurate in predicting the presence of CHD as
detected on CCTA. Risk scores are a good tool in predicting population
attributable risk but poor at demonstrating individual risk.
The anxiety associated with discovering premature CHD in a sibling
should not be underestimated. Nor should the reassurance of knowingone does not have critical CHD. In order to do this however a screening
modality is required which has a high sensitivity and hence a low false
negative rate but at the same time must also have sufﬁcient speciﬁcity
and therefore a low false positive rate. As we have illustrated above
CCTA appears to be well positioned in this respect with very high sensi-
tivity and negative predictive value, but without sacriﬁcing speciﬁcity.
EST remains the most widely used and accessible non-invasive
preliminary investigation but due to the poor relative sensitivity, with
awide variability, warrants further scrutiny. In any case it is usually per-
formed as part of exercise stress echocardiography and exercise MPI.
The high sensitivity of MPI appears to lend itself well to screening pur-
poses, but it exposes the individual to radiation without the beneﬁt of
the high speciﬁcity of CCTA. Stress echocardiography has a comparable
sensitivity to MPI, at least in a symptomatic cohort, but has the advan-
tage of a lack of radiation.
Currently CCTA does not have a strong recommendation by the AHA
or ESC for the purposes of CHD screening, but there is increasing
momentum for its use in this cohort which is likely being driven by
reducing radiation exposure and costs. As a result there are varying
practices with the use of CCTA. In the past, screening via CCTA or CAC
was discouraged in view of concern regarding the radiation dose. As
discussed above, however, the radiation dose of this modality has de-
creased signiﬁcantly in recent times due to advances of CT technology
and better scanning protocols making it more attractive as an investiga-
tional tool.
5. Summary
The prevalence of CHD in the young is not insigniﬁcant and is higher
among thosewith a family history ofMI. Assessing these individuals fur-
ther with risk score estimation and screening investigations may allow
the identiﬁcation of a high risk group in whom the risk can bemodiﬁed
and future adverse events prevented. The screening tools chosen for this
task should abide by the requirements of a suitable screening strategy.
Currently available clinical risk score lacks speciﬁcity and sensitivity
while functional stress tests lack strong clinical data for its sensitivity
and speciﬁcity. CAC has emerged as a more reliable risk predictor in
comparison with conventional risk assessment modality. CCTA is also
a potential screening tool, but it lacks clinical data, and it comes with
ionizing radiation, which has been a concern in the past.
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